NCT06142578已完成不适用
Safety and Effectiveness Clinical Evaluation of the Range of Injectable Medical Devices Fillgel in Facial Aesthetic Treatment
Kylane Laboratoires2 个研究点 分布在 1 个国家目标入组 68 人开始时间: 2022年11月14日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 68
- 试验地点
- 2
- 主要终点
- Performance
研究概览
简要总结
The study aims to confirm the safety and effectiveness of FILLGEL devices
详细描述
The primary objective is to evaluate the effectiveness of the FILLGEL range used on different treated zones one month (M1) after treatment using clinical evaluation of the global aesthetic improvement (GAIS) rated by the independent investigator. The secondary objectives of the study are to collect data for the
FILLGEL range on:
- the effectiveness of the range used on different treated zones six months (M6) and twelve months (M12) .
- the safety using clinical evaluation of the Injection Site Reactions (ISR) rated by the subject and the investigator.
- subject's satisfaction and subject's opinion on aesthetic improvement on the different treated zones.
- the injector's satisfaction on the injection quality using subjective evaluation questionnaire.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy Subject.
- •Sex: male or female.
- •Age: between 18 and 65 years.
- •Subject seeking an improvement of her/his face aspect with Hyaluronic Acid (HA) filler.
- •For group 1: Subject with moderate to severe peri-oral lines (score 3 to 5 on Bazin Upper lip scale) ;
- •For group 2: Subject with moderate to severe nasolabial folds (score 3 to 4 on WSRS scale) and/or subject with thin lips (score
- •1 or 2 for superior and/or inferior lip on the Rossi scale) and seeking an improvement of lip volume;
- •For group 3: Subject with moderate to severe cheeks/cheekbones volume deficit (score 3 to 4 on Ascher lipoatrophy scale);
- •For group 4: Subject with moderate to severe cheeks/cheekbones volume deficit (score 3 to 4 on Ascher lipoatrophy scale) and/or subject seeking improvement of chin enhancement.
- •Subject whose weight did not fluctuate in the last 6 months and who agrees to keep a stable weight during the study.
- •Subject having given their free, express, and informed consent.
- •Subject psychologically able to understand the information related to the study, and to give their written informed consent.
- •Subject registered with a social security scheme.
- •Women of childbearing potential should use a contraceptive method considered effective since at least 4 weeks and throughout the study
排除标准
- •In terms of population
- •Pregnant or nursing woman or planning a pregnancy during the study.
- •Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship.
- •Subject in a social or sanitary establishment.
- •Subject suspected to be non-compliant according to the investigator's judgment.
- •Subject having received a total of 4.500 euros as compensations for their participation in research involving human beings in the last 12 months, including their participation in the present study.
- •Subject enrolled in another study or whose non-enrollment period is not over.
- •Subject with scar(s), mole(s), hair or any other lesion on the studied zones which might interfere with the evaluation (tattoo, permanent make-up...). In terms of associated pathology
- •Subject suffering from a severe or progressive disease or any other pathology that may interfere with the evaluation of the study results and/or subject safety.
- •Subject with known history of or suffering from autoimmune disease and/or immune deficiency.
- •Subject suffering from active disease such as inflammation, infection, tumours, inflammatory and/or infectious cutaneous disorders (herpes, acne, rosacea, porphyria ...) in the 6 months before screening visit.
- •Subject with a history of streptococcal disease or an active streptococcus infection.
- •Subject prone to develop inflammatory skin conditions or having tendency to bleeding disorders
结局指标
主要结局
Performance
时间窗: 1 month
Primary endpoint was the proportion of subjects having an improvement of the zone treated with the overall FILLGEL range of devices, in all the indications, as assessed by the independent investigator, one month after treatment, using the Global Aesthetic Improvement Scale (GAIS) (subjects with a GAIS "improved", "much improved" or "very much improved"). This proportion of responders was compared to a theoretical proportion of 50%.
次要结局
- Performance - GAIS Investigator(6 months, 12 months)
- Patients Safety(Immediatly after injection (D0), 1 month, 6 months, 12 months)
- Subject Satisfaction - GAIS Subject(1, 6, 12 months)
- Injector Satisfaction(After injection)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Clinical Investigation to Assess Safety and Performance of Dermal Filler of Hyaluronic AcidSkin FoldsWrinkleNCT05450380Mesoestetic Pharma Group S.L.50
终止
不适用
Study To Assess Radiofrequency Diathermocontraction Device For Muscle Stimulation And The Treatment Of Abdominal FatMuscle StimulationAbdominal FatNCT05388617Cynosure, Inc.16
Unknown
1 期
Safety Study of Filler Agent Composed of Umbilical Cord Mesenchymal Stem Cells and Hyaluronic AcidSenescence Wrinkles, Acne, Pitting ScarNCT02698813South China Research Center for Stem Cell and Regenerative Medicine30
进行中（未招募）
不适用
Clinical Trial to Evaluate the Safety and Efficacy of Breast ImplantBreast CancerNCT01711710Seoul National University Hospital103
已完成
不适用
The Oral Accessibility Spatula (Spatule SAB)Mental HandicapNCT02818374Centre Hospitalier Régional Metz-Thionville200